Hummers Laura K
Johns Hopkins SSc Center, Baltimore, MD 21224, USA.
Curr Rheumatol Rep. 2006 Apr;8(2):131-7. doi: 10.1007/s11926-006-0053-z.
Vascular disease is universal in patients with systemic sclerosis (SSc), but there is a wide variability in its severity. It is clear that there is an early insult to the microvasculature, followed-up by on-going chronic process. This results in profound vascular damage in a subset of patients who develop severe events such as digital loss and pulmonary arterial hypertension. Although there is abundant evidence of vascular perturbation from studies of peripheral blood in SSc, there are few data about the ability to use these biomarkers to predict vascular outcomes. This paper examines the possibility of using circulating biomarkers to assess vascular disease activity and to predict severe vascular events among patients with SSc.
血管疾病在系统性硬化症（SSc）患者中普遍存在，但其严重程度差异很大。很明显，微血管系统早期受到损伤，随后是持续的慢性过程。这会导致一部分患者出现严重事件，如指端坏死和肺动脉高压，从而造成严重的血管损伤。尽管从系统性硬化症患者外周血研究中有大量血管紊乱的证据，但关于使用这些生物标志物预测血管结局的能力的数据却很少。本文探讨了使用循环生物标志物评估系统性硬化症患者血管疾病活动度及预测严重血管事件的可能性。
